Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and the best dose of veliparib when given
together with capecitabine and oxaliplatin in treating patients with advanced solid tumors.
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving veliparib together with capecitabine and oxaliplatin may kill more tumor
cells.